This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Key Predictions for Q3 Earnings Reports of LLY, BIIB, NVS
by Zacks Equity Research
The pharma/biotech industry has seen a solid start to the Q3 earnings season as evident from J&J's solid results. Let's see if the other leading players -- Lilly, Biogen and Novartis -- follow suit.
Roche (RHHBY) Reports Sales Numbers for First 9 Months
by Zacks Equity Research
Roche Holding AG's (RHHBY) reported sales of CHF39.4 billion in the first nine months of 2017, up 5% from the year-ago period.
Gilead (GILD) CAR-T Therapy Yescarta Clinches FDA Approval
by Zacks Equity Research
Gilead (GILD) wins the FDA approval for its CAR-T therapy, Yescarta, for treating refractory aggressive non-Hodgkin lymphoma.
Cancer Treatment Update: Second Gene Therapy Receives Approval
by Zacks Equity Research
The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs.
Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?
by Zacks Equity Research
The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .
What's in the Cards for Amgen (AMGN) this Earnings Season?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU
by Zacks Equity Research
Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary sclerosing cholangitis.
Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?
by Zacks Equity Research
Though ImmunoGen (IMGN) is progressing with lead ovarian cancer candidate, mirvetuximab soravtansine, the company is likely to face stiff market competition from established products upon approval.
Conatus Entrusts Keith W. Marshall With Key Management Roles
by Zacks Equity Research
Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.
Teva Submits BLA to FDA for Migraine Candidate Fremanezumab
by Zacks Equity Research
Teva Pharma (TEVA) submits BLA seeking approval for its pipeline candidate, Fremanezumab, as a preventive treatment for migraine in the United States.
Novartis Reports Positive Results on Thrombocytopenia Drug
by Zacks Equity Research
Novartis AG (NVS) announced encouraging results on Revolade from the EXTEND study.
What's in the Cards for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report third-quarter 2017 results on Oct 24.
Aerie (AERI) Up on FDA Review Committee Result for Rhopressa
by Zacks Equity Research
Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa.
Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
by Arpita Dutt
Innovation, mergers and acquisitions (M&As), strong results, product approvals and positive data flow should act as catalysts for pharma and biotech stocks.
Bristol-Myers (BMY), TARGET Extend Partnership for NASH Study
by Zacks Equity Research
Bristol-Myers Squibb (BMY) extended its strategic partnership with TARGET PharmaSolutions, Inc. for NASH study.
Lilly's Verzenio Gets Priority Review in First-Line Setting
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.
Non-Alcoholic Steatohepatitis 2017 Progress Update
by Zacks Equity Research
Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).
Lilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study
by Zacks Equity Research
Lilly's breast cancer drug, Verzenio, failed to achieve primary endpoint in a phase III study evaluating the drug as monotherapy in advanced lung cancer patients.
5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings
by Arpita Dutt
Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.
Roche (RHHBY) Receives FDA Approval For Cobas Zika Test
by Zacks Equity Research
The approval of cobas Zika will expands Roche's industry-leading donor screening portfolio for blood-borne diseases.
Lilly Wins Favorable Ruling From U.S. PTO in Alimta Dispute
by Zacks Equity Research
Lilly (LLY) has received a favorable ruling from the U.S. PTO in a dispute related to vitamin regimen patent on its key cancer drug, Alimta.
Teva Down as Mylan's Copaxone 40 mg Generic Arrives Early
by Zacks Equity Research
Teva's (TEVA) shares plunged after Mylan announced an earlier-than-expected launch of its generic version of the 40-mg thrice-weekly formulation of its blockbuster multiple sclerosis drug, Copaxone.
FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that the FDA has accepted the company's sBLA and granted Priority Review for breast cancer drug regimen Perjeta
Here's Why Bluebird Bio (BLUE) Stock Is Falling Today
by Ryan McQueeney
Shares of Bluebird Bio (BLUE), a major player in the emerging gene therapy and CAR-T research markets, slumped more than 6% in morning trading Monday after receiving a key analyst downgrade.
Ligand's Captisol Deals Set to Drive Growth in the Long Run
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, thus helping it earn milestones and royalty payments in turn.